BioCardia, Inc. (BCDA) stock
BCDANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.79−0.00 (-0.24%)
Close on Nov 17, 2026Market cap $11.93MP/E –Yield –
BioCardia revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
BioCardia's revenue for the twelve months ending Dec 31, 2025 was $0, down 100.0% year over year. For fiscal 2025 it was $0, down 100.0% from the year before. The highest annual figure on record is $1.35M in fiscal 2022.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $0 | -100.0% |
| FY2024 | Dec 31, 2024 | $58.00K | -87.8% |
| FY2023 | Dec 31, 2023 | $477.00K | -64.7% |
| FY2022 | Dec 31, 2022 | $1.35M | +33.2% |
| FY2021 | Dec 31, 2021 | $1.02M | +600.0% |
| FY2020 | Dec 31, 2020 | $145.00K | -79.6% |
| FY2019 | Dec 31, 2019 | $710.00K | +13.6% |
| FY2018 | Dec 31, 2018 | $625.00K | +30.5% |
| FY2017 | Dec 31, 2017 | $479.00K | -16.8% |
| FY2016 | Dec 31, 2016 | $576.00K | -36.3% |
| FY2015 | Dec 31, 2015 | $904.00K | +7433.3% |
| FY2011 | Dec 31, 2011 | $12.00K | – |
| FY2010 | Dec 31, 2010 | $0 | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2025 | Dec 31, 2025 | $0 | – |
| Q3 FY2025 | Sep 30, 2025 | $0 | – |
| Q2 FY2025 | Jun 30, 2025 | $0 | -100.0% |
| Q1 FY2025 | Mar 31, 2025 | $0 | -100.0% |
| Q4 FY2024 | Dec 31, 2024 | $0 | -100.0% |
| Q3 FY2024 | Sep 30, 2024 | $0 | -100.0% |
| Q2 FY2024 | Jun 30, 2024 | $3.00K | -93.0% |
| Q1 FY2024 | Mar 31, 2024 | $55.00K | -14.1% |
| Q4 FY2023 | Dec 31, 2023 | $13.00K | -87.7% |
| Q3 FY2023 | Sep 30, 2023 | $357.00K | +68.4% |
| Q2 FY2023 | Jun 30, 2023 | $43.00K | -95.6% |
| Q1 FY2023 | Mar 31, 2023 | $64.00K | +6.7% |
| Q4 FY2022 | Dec 31, 2022 | $106.00K | +34.2% |
| Q3 FY2022 | Sep 30, 2022 | $212.00K | -74.2% |
| Q2 FY2022 | Jun 30, 2022 | $974.00K | +1311.6% |
| Q1 FY2022 | Mar 31, 2022 | $60.00K | +30.4% |
| Q4 FY2021 | Dec 31, 2021 | $79.00K | +71.7% |
| Q3 FY2021 | Sep 30, 2021 | $821.00K | +2314.7% |
| Q2 FY2021 | Jun 30, 2021 | $69.00K | +155.6% |
| Q1 FY2021 | Mar 31, 2021 | $46.00K | +21.1% |
| Q4 FY2020 | Dec 31, 2020 | $46.00K | -78.6% |
| Q3 FY2020 | Sep 30, 2020 | $34.00K | -82.5% |
| Q2 FY2020 | Jun 30, 2020 | $27.00K | -68.6% |
| Q1 FY2020 | Mar 31, 2020 | $38.00K | -82.4% |
| Q4 FY2019 | Dec 31, 2019 | $215.00K | +108.7% |
| Q3 FY2019 | Sep 30, 2019 | $194.00K | +131.0% |
| Q2 FY2019 | Jun 30, 2019 | $86.00K | -64.0% |
| Q1 FY2019 | Mar 31, 2019 | $216.00K | +8.5% |
| Q4 FY2018 | Dec 31, 2018 | $103.00K | +3.0% |
| Q3 FY2018 | Sep 30, 2018 | $84.00K | -35.4% |
| Q2 FY2018 | Jun 30, 2018 | $239.00K | +113.4% |
| Q1 FY2018 | Mar 31, 2018 | $199.00K | +45.3% |
| Q4 FY2017 | Dec 31, 2017 | $100.00K | -27.0% |
| Q3 FY2017 | Sep 30, 2017 | $130.00K | +11.1% |
| Q2 FY2017 | Jun 30, 2017 | $112.00K | – |
| Q1 FY2017 | Mar 31, 2017 | $137.00K | – |
| Q4 FY2016 | Dec 31, 2016 | $137.00K | – |
| Q3 FY2016 | Sep 30, 2016 | $117.00K | – |
See a number that looks wrong?